This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Abstract Cardio-oncology is a rapidly growing field of cardiovascular (CV) medicine that has resulted from the continuously increasing clinical demand for specialized CV evaluation, prevention and management of patients suffering or surviving from malignant diseases.
New research published in JACC: CardioOncology shows that air pollution plays a significant role in increasing cardiovascular disease and mortality in cancer patients and contributes to health disparities related to these conditions. “The The new study was motivated by a need to fill that gap, Rao said.
The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. Circulation, Ahead of Print.
This evidence calls for expanded research to validate and extend these preliminary observations, emphasizing the importance of further investigation into cangrelor's applications in complex patient care scenarios.
The American College of Cardiology’s Cardiac Oncology Conference, “Advancing the Cardiovascular Care of the Oncology Patient,” will be held in Washington, D.C., Cardio-Oncology Educational Training: What Do I Need to Learn? 9-11, 2024. 9-11, 2024, with program planners preparing a robust program. How to Structure?:
There is need for development of a stronger evidence base to guide clinical practice in cardio-oncology. The establishment of multicentre international registries and national-level healthcare data linkage projects are important steps towards facilitating enrichment of cardio-oncologyresearch programmes.
Cardio-oncology is a new field of interest in cardiology focusing on the detection and treatment of cardiovascular diseases, such as arrhythmias, myocarditis, and heart failure, as side-effects of chemotherapy and radiotherapy. The association between chemotherapeutic agents and arrhythmias has previously been established.
This includes the establishment of networks dedicated to its management, education, and research, as well as Late-Breaking Science. EAS Congress explores the latest research developments into the causes of atherosclerosis and related vascular disease. Fees: Visit AHA 2024 website for registration options. Hashtag: #AHA24 11.
For more cardiology research news join our newsletter or follow us on Twitter , Facebook , LinkedIn or Instagram. There were many important developments in presented in key clinical trial presentations and publications stemming from the AHA Scientific Sessions 2023. Learn more about AHA 2023 highlights.
The Impact of Childhood Cancer on Future Risk of Death Previous research has demonstrated that childhood cancer survivors have an increased risk for heart disease and a higher incidence of cardiovascular mortality compared to the general public. Collaborators on Bottinor’s research include Eric Chow M.D., Wendy Bottinor, MD.
The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5). Conducted at 15 research hospitals across South Korea, Japan, Taiwan, and New Zealand, the trial enrolled 1606 patients. Author: Kelly Schoonderwoerd References Butler J et al. New Engl J Med.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content